SG10202108307YA - Rna cancer vaccines - Google Patents
Rna cancer vaccinesInfo
- Publication number
- SG10202108307YA SG10202108307YA SG10202108307YA SG10202108307YA SG10202108307YA SG 10202108307Y A SG10202108307Y A SG 10202108307YA SG 10202108307Y A SG10202108307Y A SG 10202108307YA SG 10202108307Y A SG10202108307Y A SG 10202108307YA SG 10202108307Y A SG10202108307Y A SG 10202108307YA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer vaccines
- rna cancer
- rna
- vaccines
- cancer
- Prior art date
Links
- 229940022399 cancer vaccine Drugs 0.000 title 1
- 238000009566 cancer vaccine Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453444P | 2017-02-01 | 2017-02-01 | |
| US201762453465P | 2017-02-01 | 2017-02-01 | |
| US201762558238P | 2017-09-13 | 2017-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202108307YA true SG10202108307YA (en) | 2021-08-30 |
Family
ID=63040027
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906895WA SG11201906895WA (en) | 2017-02-01 | 2017-10-26 | Rna cancer vaccines |
| SG10202108307YA SG10202108307YA (en) | 2017-02-01 | 2017-10-26 | Rna cancer vaccines |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906895WA SG11201906895WA (en) | 2017-02-01 | 2017-10-26 | Rna cancer vaccines |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190351040A1 (en) |
| EP (1) | EP3576751A4 (en) |
| JP (2) | JP2020506189A (en) |
| KR (1) | KR20190120233A (en) |
| CN (1) | CN110505877A (en) |
| AU (1) | AU2017397458A1 (en) |
| CA (1) | CA3052255A1 (en) |
| MA (1) | MA47401A (en) |
| NZ (1) | NZ755780A (en) |
| RU (2) | RU2768829C2 (en) |
| SG (2) | SG11201906895WA (en) |
| WO (1) | WO2018144082A1 (en) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CN106659803A (en) | 2014-04-23 | 2017-05-10 | 摩登纳特斯有限公司 | Nucleic acid vaccines |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| US11007260B2 (en) | 2015-07-21 | 2021-05-18 | Modernatx, Inc. | Infectious disease vaccines |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| CA3002912A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Tropical disease vaccines |
| WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| HUE059127T2 (en) | 2015-10-22 | 2022-10-28 | Modernatx Inc | Respiratory virus vaccines |
| US20180289792A1 (en) | 2015-10-22 | 2018-10-11 | ModernaTX. Inc. | Sexually transmitted disease vaccines |
| EP3386484B1 (en) | 2015-12-10 | 2022-03-30 | ModernaTX, Inc. | Compositions and methods for delivery of therapeutic agents |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| WO2017161349A1 (en) | 2016-03-18 | 2017-09-21 | Immune Sensor, Llc | Cyclic di-nucleotide compounds and methods of use |
| US20190343942A1 (en) * | 2016-04-22 | 2019-11-14 | Curevac Ag | Rna encoding a tumor antigen |
| MA45051A (en) | 2016-05-18 | 2019-03-27 | Modernatx Inc | RELAXIN-CODING POLYNUCLEOTIDES |
| WO2018053209A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
| CA3041307A1 (en) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
| US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
| US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| WO2018111967A1 (en) | 2016-12-13 | 2018-06-21 | Modernatx, Inc. | Rna affinity purification |
| WO2018151816A1 (en) | 2017-02-16 | 2018-08-23 | Modernatx, Inc. | High potency immunogenic compositions |
| US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
| WO2018170256A1 (en) * | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018170260A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| WO2018170347A1 (en) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| MA48047A (en) | 2017-04-05 | 2020-02-12 | Modernatx Inc | REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY |
| MA49421A (en) | 2017-06-15 | 2020-04-22 | Modernatx Inc | RNA FORMULATIONS |
| CN111212905A (en) | 2017-08-18 | 2020-05-29 | 摩登纳特斯有限公司 | RNA polymerase variants |
| EP3668977A4 (en) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | Analytical hplc methods |
| MA49922A (en) | 2017-08-18 | 2021-06-02 | Modernatx Inc | PROCESSES FOR HPLC ANALYSIS |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | Zika virus rna vaccines |
| MA54676A (en) | 2018-01-29 | 2021-11-17 | Modernatx Inc | RSV RNA VACCINES |
| SG11202012770RA (en) * | 2018-06-27 | 2021-01-28 | Modernatx Inc | Personalized cancer vaccine epitope selection |
| JP2022506839A (en) * | 2018-11-07 | 2022-01-17 | モデルナティエックス インコーポレイテッド | RNA cancer vaccine |
| TW202043256A (en) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | Prostate neoantigens and their uses |
| JP2022518399A (en) * | 2019-01-14 | 2022-03-15 | ジェネンテック， インコーポレイテッド | How to Treat Cancer with PD-1 Axial Binding Antagonists and RNA Vaccines |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| AU2020224103A1 (en) | 2019-02-20 | 2021-09-16 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
| US20220218808A1 (en) * | 2019-05-02 | 2022-07-14 | University Of Florida Research Foundation, Inc. | Compositions for treatment of diffuse intrinsic pontine glioma |
| MA56060A (en) * | 2019-05-31 | 2022-04-06 | Modernatx Inc | EXPANDED T LYMPHOCYTE ASSAY |
| CN110172480B (en) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | Double-antigen epitope fusion gene recombinant lentiviral vector, antigen presenting cell and CTL cell as well as construction method and application thereof |
| CN110172089B (en) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | KRAS mutant multi-antigen combination, targeting KRAS mutant tumor CTL and application thereof |
| WO2021119418A1 (en) * | 2019-12-11 | 2021-06-17 | Vanderbilt University | Methods of synthesizing mrna and functional proteins from synthetic double stranded dna |
| AU2021213812A1 (en) * | 2020-01-30 | 2022-08-04 | Modernatx, Inc. | mRNAs encoding metabolic reprogramming polypeptides and uses thereof |
| EP4096708A1 (en) * | 2020-01-31 | 2022-12-07 | Genentech, Inc. | Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine |
| WO2021158996A1 (en) * | 2020-02-05 | 2021-08-12 | University Of Florida Research Foundation, Incorporated | Rna-loaded nanoparticles and use thereof for the treatment of cancer |
| MX2022011018A (en) * | 2020-03-11 | 2022-12-15 | Advansix Resins & Chemicals Llc | Surfactants for healthcare products. |
| JP2023522193A (en) * | 2020-04-17 | 2023-05-29 | ザ フランシス クリック インスティチュート リミティッド | antigen pool |
| EP4138897A1 (en) | 2020-04-22 | 2023-03-01 | BioNTech SE | Coronavirus vaccine |
| US11130787B2 (en) * | 2020-06-11 | 2021-09-28 | MBF Therapeutics, Inc. | Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods |
| JP2023533721A (en) | 2020-07-02 | 2023-08-04 | ライフ テクノロジーズ コーポレーション | Trinucleotide cap analogues, their preparation and use |
| EP4194006A1 (en) * | 2020-08-04 | 2023-06-14 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
| CA3191433A1 (en) | 2020-08-12 | 2022-02-17 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2022086140A1 (en) | 2020-10-20 | 2022-04-28 | 에스티팜 주식회사 | Oligonucleotide for 5'-capped rna synthesis |
| EP4232036A1 (en) * | 2020-10-22 | 2023-08-30 | The Regents of University of California | Monoamine oxidase blockade therapy for treating cancer through regulating tumor associated macrophages (tams) |
| WO2022120560A1 (en) * | 2020-12-08 | 2022-06-16 | 深圳市瑞吉生物科技有限公司 | Immunosuppressant in mrna dosage form and application thereof in preparation of medicament for treating tumors |
| WO2022140278A1 (en) * | 2020-12-21 | 2022-06-30 | University Of Florida Research Foundation, Inc. | Multilamellar rna nanoparticle vaccine against cancer |
| CN114717229A (en) * | 2021-01-05 | 2022-07-08 | 麦塞拿治疗(香港)有限公司 | Cell-free and vector-free in vitro RNA transcription methods and nucleic acid molecules for therapeutic mRNA |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| WO2022204491A1 (en) * | 2021-03-26 | 2022-09-29 | Modernatx, Inc. | Pertussis vaccine |
| NL2028681B1 (en) * | 2021-04-02 | 2022-10-17 | Nutcracker Therapeutics Inc | Materials and methods for generating antigen-specific t cells and treating diseases |
| CN113186285B (en) * | 2021-05-10 | 2022-05-24 | 深圳市展行生物有限公司 | Method for auxiliary diagnosis of gastric cancer and miRNA combination used in method |
| CN113577258B (en) * | 2021-07-31 | 2024-04-16 | 山东兴瑞生物科技有限公司 | Double-target mRNA vaccine and preparation method thereof |
| CN115703714A (en) * | 2021-08-13 | 2023-02-17 | 广州谷森制药有限公司 | Novel cationic lipid compounds |
| EP4147712A1 (en) | 2021-09-13 | 2023-03-15 | OncoDNA | Method to generate a double-stranded dna pool encoding neoantigens of a tumor of a patient |
| EP4147713A1 (en) * | 2021-09-13 | 2023-03-15 | OncoDNA | A rna vaccine comprising an rna pool generated from a double-stranded dna pool |
| CA3230568A1 (en) | 2021-09-13 | 2023-03-16 | Jean-Pol DETIFFE | Method to generate a double-stranded dna pool encoding neoantigens of a tumor of a patient |
| WO2023086796A2 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
| WO2023125974A1 (en) * | 2021-12-31 | 2023-07-06 | 广州国家实验室 | Mrna vaccine |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| WO2024026490A1 (en) * | 2022-07-28 | 2024-02-01 | Sqz Biotechnologies Company | Polynucleotides encoding linked antigens and uses thereof |
| WO2024075851A1 (en) * | 2022-10-07 | 2024-04-11 | 国立大学法人 筑波大学 | Design method and production method for nucleic acid construct and protein complex |
| EP4364752A1 (en) | 2022-11-07 | 2024-05-08 | OncoDNA | Improved vaccine |
| CN116970614A (en) * | 2022-12-29 | 2023-10-31 | 达冕疫苗(广州)有限公司 | Compositions and methods for ribonucleic acid vaccines encoding NY-ESO-1 |
| CN117883558A (en) * | 2024-03-15 | 2024-04-16 | 山东兴瑞生物科技有限公司 | Preparation method of personalized mRNA vaccine for targeting liver tumor |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010037408A1 (en) * | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| BR112012029066A2 (en) * | 2010-05-14 | 2020-09-01 | The General Hospital Corporation | compositions and processes for the identification of tumor-specific neoantigens. |
| WO2012159643A1 (en) * | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| SI3473267T1 (en) * | 2011-05-24 | 2022-01-31 | BioNTech SE | Individualized vaccines for cancer |
| US9371380B2 (en) * | 2011-08-16 | 2016-06-21 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent and therapeutic effect prediction method for patients with KRAS-mutated colorectal cancer |
| CA2846043A1 (en) * | 2011-08-31 | 2013-03-07 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| US9192651B2 (en) * | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
| EP2968530A4 (en) * | 2013-03-15 | 2016-04-06 | Univ Pennsylvania | Vaccines with biomolecular adjuvants |
| US20160367651A1 (en) * | 2013-10-01 | 2016-12-22 | Mie University | T cell inducing vaccine containing an interepitope sequence that promotes antigen presentation |
| EP3169693B1 (en) * | 2014-07-16 | 2022-03-09 | ModernaTX, Inc. | Chimeric polynucleotides |
| WO2016128060A1 (en) * | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| AU2016251687C1 (en) * | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
| WO2016201377A1 (en) * | 2015-06-10 | 2016-12-15 | Moderna Therapeutics, Inc. | Targeted adaptive vaccines |
| EP3328394A4 (en) * | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | Concatemeric peptide epitope rnas |
| CA3003090A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Cancer vaccines |
| KR20190086681A (en) * | 2016-10-26 | 2019-07-23 | 모더나티엑스, 인크. | Messenger ribonucleic acid and method of use thereof for improving immune response |
-
2017
- 2017-10-26 EP EP17894869.1A patent/EP3576751A4/en active Pending
- 2017-10-26 NZ NZ755780A patent/NZ755780A/en unknown
- 2017-10-26 RU RU2019127381A patent/RU2768829C2/en active
- 2017-10-26 SG SG11201906895WA patent/SG11201906895WA/en unknown
- 2017-10-26 CA CA3052255A patent/CA3052255A1/en active Pending
- 2017-10-26 CN CN201780089255.1A patent/CN110505877A/en active Pending
- 2017-10-26 WO PCT/US2017/058595 patent/WO2018144082A1/en unknown
- 2017-10-26 MA MA047401A patent/MA47401A/en unknown
- 2017-10-26 JP JP2019541415A patent/JP2020506189A/en active Pending
- 2017-10-26 AU AU2017397458A patent/AU2017397458A1/en active Pending
- 2017-10-26 US US16/482,844 patent/US20190351040A1/en active Pending
- 2017-10-26 RU RU2022106357A patent/RU2022106357A/en unknown
- 2017-10-26 KR KR1020197025539A patent/KR20190120233A/en not_active IP Right Cessation
- 2017-10-26 SG SG10202108307YA patent/SG10202108307YA/en unknown
-
2023
- 2023-09-08 JP JP2023146197A patent/JP2023164537A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023164537A (en) | 2023-11-10 |
| RU2022106357A (en) | 2022-03-24 |
| US20190351040A1 (en) | 2019-11-21 |
| EP3576751A4 (en) | 2021-08-04 |
| NZ755780A (en) | 2023-10-27 |
| SG11201906895WA (en) | 2019-08-27 |
| MA47401A (en) | 2021-05-05 |
| EP3576751A1 (en) | 2019-12-11 |
| JP2020506189A (en) | 2020-02-27 |
| WO2018144082A1 (en) | 2018-08-09 |
| RU2768829C2 (en) | 2022-03-24 |
| KR20190120233A (en) | 2019-10-23 |
| CN110505877A (en) | 2019-11-26 |
| RU2019127381A (en) | 2021-03-02 |
| CA3052255A1 (en) | 2018-08-09 |
| AU2017397458A1 (en) | 2019-08-15 |
| RU2019127381A3 (en) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10202108307YA (en) | Rna cancer vaccines | |
| ZA201905396B (en) | Trans-replicating rna | |
| EP3876947A4 (en) | Rna cancer vaccines | |
| SG10201913631TA (en) | Rna for cancer therapy | |
| IL264023A (en) | Nant cancer vaccine | |
| EP3364949A4 (en) | Cancer vaccines | |
| IL268894A (en) | Therapeutic rna | |
| IL259017A (en) | Targeted cancer therapy | |
| SI3373959T1 (en) | Arenavirus particles as cancer vaccines | |
| HK1257910A1 (en) | Ovarian cancer vaccines | |
| IL292272A (en) | Cancer vaccine | |
| IL277752A (en) | Cancer vaccines | |
| GB201519734D0 (en) | Cancer therapy | |
| GB201608821D0 (en) | Vaccines | |
| IL260988A (en) | Ptps-based vaccines against cancer | |
| GB2546773B (en) | Cancer | |
| GB201807831D0 (en) | Cancer Vaccine | |
| GB201712904D0 (en) | Vaccine | |
| GB201707785D0 (en) | Vaccination | |
| GB201706798D0 (en) | Vaccination | |
| GB201704892D0 (en) | Improved vaccines | |
| GB201704126D0 (en) | Vaccine | |
| GB201703809D0 (en) | Vaccine | |
| GB201614387D0 (en) | Improved vaccines | |
| GB201511609D0 (en) | Cancer therapy |